EA200100783A1 - COMPOUNDS - D1 DOPAMINE RECEPTOR AGONISTS - Google Patents

COMPOUNDS - D1 DOPAMINE RECEPTOR AGONISTS

Info

Publication number
EA200100783A1
EA200100783A1 EA200100783A EA200100783A EA200100783A1 EA 200100783 A1 EA200100783 A1 EA 200100783A1 EA 200100783 A EA200100783 A EA 200100783A EA 200100783 A EA200100783 A EA 200100783A EA 200100783 A1 EA200100783 A1 EA 200100783A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrogen
halogen
together form
cyclohexane ring
compounds
Prior art date
Application number
EA200100783A
Other languages
Russian (ru)
Other versions
EA004745B1 (en
Inventor
Гари Тилбрук
Original Assignee
Синес Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синес Лимитед filed Critical Синес Лимитед
Publication of EA200100783A1 publication Critical patent/EA200100783A1/en
Publication of EA004745B1 publication Critical patent/EA004745B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Данное изобретение предлагает 2,3,4,5-тетрагидро-1H-3-бензазепины общей формулы (I), где Rпредставляет собой водород, галоген, C-C-алкил или CF; Rпредставляет собой водород, метил или низший алкенил с 3-5 атомами углерода; Rи Rвместе образуют фурановое, дигидрофурановое, тиофеновое, дигидротиофеновое, циклопентановое или циклогексановое кольцо и Rпредставляет собой водород или Rи Rвместе образуют фурановое, дигидрофурановое, тиофеновое, дигидротиофеновое, циклопентановое или циклогексановое кольцо и Rпредставляет собой водород; Rпредставляет собой водород, галоген, CF, CN, NO, или NH; Rпредставляет собой водород, галоген, CF, CN, NOили NH. Исключена определенная комбинация заместителей: R=H, R=H, и Rи R, вместе образуют циклогексановое кольцо, а именно 1-(5,6,7,8-тетрагидронафтален-2-ил)-2,3,4,5-тетрагидро-1H-бензол[d]азепин-7,8-диол. Соединения по изобретению предложены в качестве терапевтических агентов, которые селективно позитивно взаимодействуют с постсинаптическими дофаминовыми рецепторами D1 в полосатом теле, прямо или косвенно, (называемые дофаминовыми D1-агонистами) и являются чрезвычайно полезными в качестве антипаркинсонических агентов.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula (I), where R <1> is hydrogen, halogen, C C-C alkyl or CF; R4 is hydrogen, methyl or lower alkenyl of 3 to 5 carbon atoms; R and together form a furan, digidrofuranovoe, thiophene, digidrotiofenovoe, cyclopentane or cyclohexane ring and R is hydrogen or R together form a furan, digidrofuranovoe, thiophene, digidrotiofenovoe, cyclopentane or cyclohexane ring and R is hydrogen; R4 is hydrogen, halogen, CF, CN, NO, or NH; R 4 is hydrogen, halogen, CF, CN, NO or NH. A certain combination of substituents is excluded: R = H, R = H, and R and R, together form a cyclohexane ring, namely 1- (5,6,7,8-tetrahydronaphthalen-2-yl) -2,3,4,5- tetrahydro-1H-benzene [d] azepine-7,8-diol. The compounds of the invention are proposed as therapeutic agents that selectively positively interact with postsynaptic dopamine D1 receptors in the striatum, directly or indirectly (called dopamine D1 agonists) and are extremely useful as antiparkinsonian agents. The international application was published together with the report international search.

EA200100783A 1999-02-17 2000-02-17 Tetrahydrobenzazepine derivatives as dopamined1 receptors EA004745B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903671.7A GB9903671D0 (en) 1999-02-17 1999-02-17 Dopamine D-1 receptor agonist compounds
PCT/GB2000/000570 WO2000049000A1 (en) 1999-02-17 2000-02-17 Dopamine d1 receptor agonist compounds

Publications (2)

Publication Number Publication Date
EA200100783A1 true EA200100783A1 (en) 2002-02-28
EA004745B1 EA004745B1 (en) 2004-08-26

Family

ID=10847990

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100783A EA004745B1 (en) 1999-02-17 2000-02-17 Tetrahydrobenzazepine derivatives as dopamined1 receptors

Country Status (17)

Country Link
EP (1) EP1157009A1 (en)
JP (1) JP2002537288A (en)
KR (1) KR20010108228A (en)
CN (1) CN1142916C (en)
AU (1) AU767332B2 (en)
BR (1) BR0008329A (en)
CA (1) CA2363695A1 (en)
CZ (1) CZ20012973A3 (en)
EA (1) EA004745B1 (en)
GB (1) GB9903671D0 (en)
HU (1) HUP0200057A3 (en)
IL (1) IL144810A0 (en)
MX (1) MXPA01008294A (en)
NO (1) NO20013978L (en)
PL (1) PL349838A1 (en)
WO (1) WO2000049000A1 (en)
ZA (1) ZA200106478B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
KR20080044840A (en) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006278514A1 (en) * 2005-08-03 2007-02-15 Mia Levite Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells by dopamine D1R agonists
CN101684096A (en) * 2008-09-23 2010-03-31 中国科学院上海药物研究所 Novel benzoazepine compound and preparation method and application thereof
CN102276531A (en) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 Method for preparing fenoldopam mesylate
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561305A (en) * 1975-07-02 1980-02-20 Smithkline Corp Benzazepine derivatives and pharmeceutical compositions containing them
US4111957A (en) * 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4265889A (en) * 1978-05-05 1981-05-05 Smithkline Corporation 6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4707483A (en) * 1985-12-20 1987-11-17 Smithkline Beckman Corporation 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders
US4861771A (en) * 1989-01-27 1989-08-29 Smithkline Beckman Corporation Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs

Also Published As

Publication number Publication date
AU2563200A (en) 2000-09-04
WO2000049000A1 (en) 2000-08-24
ZA200106478B (en) 2002-02-07
HUP0200057A2 (en) 2002-08-28
NO20013978D0 (en) 2001-08-15
CN1341102A (en) 2002-03-20
NO20013978L (en) 2001-08-15
BR0008329A (en) 2002-01-29
MXPA01008294A (en) 2002-07-02
AU767332B2 (en) 2003-11-06
EP1157009A1 (en) 2001-11-28
KR20010108228A (en) 2001-12-07
CN1142916C (en) 2004-03-24
CZ20012973A3 (en) 2002-01-16
GB9903671D0 (en) 1999-04-14
IL144810A0 (en) 2002-06-30
EA004745B1 (en) 2004-08-26
HUP0200057A3 (en) 2004-03-29
PL349838A1 (en) 2002-09-23
CA2363695A1 (en) 2000-08-24
JP2002537288A (en) 2002-11-05

Similar Documents

Publication Publication Date Title
RU2386626C2 (en) 1a, 5a-TETRAHYDRO-S-THIACYCLOPROPA[a]PENTALENES: TRICYCLIC DERIVATIVES OF THIOPHENE AS S1P1/EDG1 RECEPTOR AGONISTS
EA199800051A1 (en) DERIVATIVES OF BENZAMIDE AND THEIR APPLICATION AS ANTAGONISTS VAZOPRESSIN
EA199800579A1 (en) NEW DERIVATIVES 5-AMINO-3-CYANO-4-ETYLSULPHINYL-1-PHENYLPYRAZOLE AND THEIR USE AS PESTICIDES
PE20061335A1 (en) BENZODIOXANE AND BENZODIOXOLANE DERIVED COMPOUNDS AS MODULATORS OF THE 5-HT2C RECEPTOR
PE20061297A1 (en) CHROME AND CHROME DERIVED COMPOUNDS MODULATING THE SEROTONIN 5-HT2C RECEPTOR
PE20000339A1 (en) BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS
EA200400748A1 (en) RECEPTOR AGONISTS ACTIVATED BY PEROXISOMIC PROLIFERATOR
UA95454C2 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE326453T1 (en) ANTITHRBOTIC AMIDES
EA200701640A1 (en) NEW CONNECTIONS WITH THERAPEUTIC EFFECT
EA200100696A1 (en) METHOD OF OBTAINING 5-CYANOPHTHALIDE
EA200600348A1 (en) NEW CONNECTIONS
EA200400762A1 (en) NEW CONNECTIONS, THEIR USE IN MEDICINE, THE WAY OF THEIR MANUFACTURE AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200300519A1 (en) CONNECTIONS OF DERIVATIVES OF BENZOTHIOPHENE, THE METHOD OF THEIR RECEPTION AND APPLICATION
KR950032152A (en) Acetamide
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
EA200100783A1 (en) COMPOUNDS - D1 DOPAMINE RECEPTOR AGONISTS
DE60007745D1 (en) Heterocyclic aminopyrrolidone derivatives as melatoninergic agents
ATE409180T1 (en) SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES
EA200301317A1 (en) DERIVATIVES OF AMINOHINOLINE AND ITS APPLICATION AS A3 LOSE Adenosine Ligands
DE60123643D1 (en) BENZIMIDAZOLON DERIVATIVES WITH AFFINITY TO SEROTONIN AND DOPAMINE RECEPTORS
ECSP045121A (en) RECEIVER AGONISTS ACTIVATED BY PEROXISOM PROLIFERATOR
YU44301A (en) 5ht1 antagonists for antidepressant therapy
EA200200727A1 (en) NEW INDOL DERIVATIVES
FR2801585B1 (en) NEW II-8 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU